Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Duloxetine plus electroconvulsive therapy safety study in treatment-resistant depression
IRCT20181204041847N1Phase 3Completed
- Sponsor
- Shiraz University of Medical Sciences
- Start
- Dec 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial in treatment-resistant depression (TRD) comparing Electroconvulsive therapy plus duloxetine group with Electroconvulsive therapy plus sertraline group (2 arms). Primary endpoints: Convulsion duration, Electrocardiogram and 4 more. Started Dec 2018; status: completed.
02
Drugs
duloxetinesertraline
03
Conditions
treatment-resistant depression (TRD)
Beyond the preview
Go deeper on IRCT20181204041847N1.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20181204041847N1.